Core Viewpoint - Yinno Pharmaceuticals-B (02591) has successfully listed its shares at a price of HKD 18.68, with a significant increase of 285.44% to HKD 72 at the time of reporting, indicating strong market interest and investor confidence in the company's potential [1] Company Overview - The company focuses on providing high-quality medications for patients with metabolic diseases, with a current pipeline that includes the core product, Isupatide α, aimed at treating obesity and metabolic dysfunction-related fatty liver disease (MASH) [1] - Isupatide α, previously known as Suparutide and branded as Yinuo Qing, is expected to receive approval from the National Medical Products Administration of China in January 2025, making it the first domestically developed humanized long-acting GLP-1 receptor agonist in China [1] Product Pipeline - The company is also developing Isupatide α for indications related to weight loss and metabolic dysfunction-associated fatty liver disease, addressing significant unmet medical needs in these areas [1] - In addition to Isupatide α, the company has five other drug candidates in the preclinical stage, indicating a robust pipeline for future growth [1]